Immunotherapy-Related Colitis: A 'Hot Topic'

Patients who develop immunotherapy-related colitis tend to have better outcomes, so it is important to get them back on treatment as soon as possible.

Immunotherapy-related colitis is a "hot topic" in the world of oncology, according to Yinghong Wang, MD, PhD, MS, gastroenterologist, Department of Gastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center. It is important that the healthcare team treat patients with colitis quickly and effectively, so that they can get back on treatment as soon as possible, and stay on treatment as well.


This is a hot topic because we see so many patients who have colitis from checkpoint inhibitors and we want to improve our quality of service to get the patients’ symptoms under control as soon as possible and as effectively as possible. Patients who develop GI-related toxicity tend to have a better cancer outcome. Therefore, our goal is to put them back on the immunotherapy as fast as possible and keep them on as long as possible.

Related Videos
Karyn Goodman
Reanne Booker on Factors to Consider When Discussing Palliative Radiation
Grace Choong
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Related Content
© 2023 MJH Life Sciences

All rights reserved.